Most Recent
The Australian Securities and Investments Commission has filed long-awaited action against troubled tech company Nuix and a handful of former and current directors over allegedly misleading revenue announcements to investors.
The Australian Securities and Investments Commission has suffered a defeat in proceedings alleging the Commonwealth Bank of Australia accepted conflicted remuneration through the sale of its Essential Super product, with a judge finding the regulator "ignored the circumstances" in which the product was distributed.
J Hutchinson and the CFMEU have appealed a judgment slapping them with a combined $1.35 million penalty for agreeing to boycott an independent subcontractor at a Brisbane construction site.
Telecommunications giant Optus may face a class action over a cyberattack that left the data of up to 10 million current and former customers exposed.
The former CEO of Blue Star Helium has asked the High Court to throw out a $40,000 penalty and four-year ban imposed on him after the company failed to disclose to shareholders the identity of the buyer behind a botched sale of Texas oil assets.
A judge has imposed a $14.5 million penalty on five AMP entities, saying it was “surprising and concerning” that the wealth manager deducted $356,000 from customers' superannuation accounts for advice they never received, despite numerous complaints.
The consumer regulator has taken a page from ASIC, warning it will take action against businesses that make unsupported environmental or sustainability claims.
Two receivers for unlicensed investment scheme A One Multi Services have lost their bid to have 85 per cent of their future remuneration paid out immediately, with a judge agreeing with the corporate regulator that the receivers should not have “what are in effect trust funds”.
A judge has signed off on a $7.2 million penalty against Dixon Advisory after the company admitted to ASIC allegations that its advisors failed to act in its clients' best interests by recommending they invest in a risky US-based real estate investment fund.
The Australian unit of Mylan is challenging the ATO's rejection of a $48 million deduction for 2020 in the generic drug company's latest spat with the tax office over interest on loans to fund its $1.2 billion acquisition of generic drug maker Alphapharm.